However, these therapies are associated with high cost and side effects, including gastrointestinal toxicity, jaw osteonecrosis, atypical fractures, breast cancer and thromboembolism, which limit their clinical application.38, 39 The present study is the first to show that STA inhibits osteoclast formation and bone resorption by suppressing RANKL‐induced activation of NF‐κB–NFATc1 signalling in vitro. The gene discussed is NFATC1; the disease is Thromboembolism.